Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. Azacitidine is a
hypomethylating agent (HMA) used to treat MDS. In this study, patients with intermediate- or
high-risk MDS will receive treatment with mocetinostat and azacitidine to evaluate the safety
of the study treatment. Safety assessments will include echocardiograms, electrocardiograms
and routine safety laboratory studies (hematology and serum chemistry). In addition, clinical
response to treatment will be monitored using bone marrow aspirates or biopsies, and other
routine methods.